以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。
数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15
Daraxonrasib
13 atoms · 跨 3 天 · 首见 2026-05-31 · 最近 2026-06-02
三色: 🟦 fact 11 · 🟥 take 2 · stance ▲10/▼0/◆3
来源: X 13
时态: fresh:13
标签: 好数字:12 · 好信源:8 · 好观点:1
预测 (forecast) (2)
- 2026-06-02 · 美国上市时间
这款药预计美国今年Q3上市
tags: 好数字 · → daily
value: date=Q3 2026
- 2026-06-02 · 中国上市时间
中国上市预计在明后年
tags: 好数字 · → daily
value: date=2027-2028
事实 (fact) (11)
- 2026-05-31 ⭐ · RASolute 302 Phase 3 OS RAS G12 population result
OS in RAS G12 population 13.2 vs 6.6 months HR 0.40 P<0.001
tags: 好数字·好信源 · → daily
value: qty=13.2 vs 6.6 months · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 OS overall population result
OS in overall population 13.2 vs 6.7 months HR 0.40 P<0.001
tags: 好数字·好信源 · → daily
value: qty=13.2 vs 6.7 months · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 PFS RAS G12 population result
PFS in RAS G12 population 7.3 vs 3.5 months HR 0.45 P<0.001
tags: 好数字·好信源 · → daily
value: qty=7.3 vs 3.5 months · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 PFS overall population result
PFS in overall population 7.2 vs 3.6 months HR 0.49 P<0.001
tags: 好数字·好信源 · → daily
value: qty=7.2 vs 3.6 months · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 12-month OS overall population result
12-month OS Overall population: 53.2% vs 17.3%
tags: 好数字·好信源 · → daily
value: qty=53.2% vs 17.3% · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 Grade ≥3 AEs rate
Grade ≥3 AEs: 61.8% vs 69.6%
tags: 好数字·好信源 · → daily
value: qty=61.8% vs 69.6% · date=2026-05-31
- 2026-05-31 ⭐ · RASolute 302 Phase 3 TRAEs leading to discontinuation rate
TRAEs leading to discontinuation: 1.2% vs 11.2%
tags: 好数字·好信源 · → daily
value: qty=1.2% vs 11.2% · date=2026-05-31
- 2026-06-01 · mOS in previously treated mPDAC Phase 3 trial
Daraxonrasib doubled mOS in previously treated mPDAC in a Phase 3 trial (13.2 vs. 6.7 months)
tags: 好数字·好信源 · → daily
value: qty=13.2 vs 6.7 months · date=Phase 3 trial
- 2026-06-02 · 胰腺癌死亡率降低幅度
Daraxonrasib这款靶向药公布了临床数据，将胰腺癌的死亡率降低了60%
tags: 好数字 · → daily
value: qty=60% · direction=down
- 2026-05-31 · OS vs 化疗在RAS G12转移性胰腺癌
Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
tags: 好数字 · → daily
value: qty=13.2 vs 6.6 months
- 2026-06-02 · 副作用比较
副作用远小于化疗
tags: 好观点 · → daily
value: direction=less
时间轴 (近 20)
- 2026-06-02 ·
fact · 胰腺癌死亡率降低幅度 · → daily
- 2026-06-02 ·
fact · 副作用比较 · → daily
- 2026-06-02 ·
forecast · 美国上市时间 · → daily
- 2026-06-02 ·
forecast · 中国上市时间 · → daily
- 2026-06-01 ·
fact · mOS in previously treated mPDAC Phase 3 trial · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 OS RAS G12 population result · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 OS overall population result · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 PFS RAS G12 population result · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 PFS overall population result · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 12-month OS overall population result · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 Grade ≥3 AEs rate · → daily
- 2026-05-31 ·
fact · RASolute 302 Phase 3 TRAEs leading to discontinuation rate · → daily
- 2026-05-31 ·
fact · OS vs 化疗在RAS G12转移性胰腺癌 · → daily
← 实体目录 · 系统日志